安全使用质子抑制剂
Carlos Martín de Argila de Prados1, Julia López Cardona1, Federico Argüelles-Arias2
1Gastroenterología y Hepatología, Hospital Universitario Ramón y Cajal, España.
Revista espanola de enfermedades digestivas
|July 31, 2023
概括
质子抑制剂 (PPI) 广泛使用,但可能会导致骨折和营养缺乏等不良影响. 定期审查PPI处方是确保适当使用和最大限度地降低风险的必要条件.
科学领域:
- 胃肠病学 胃肠病学
- 药理学 药理学是指药理学的学科.
- 内部医学 内部医学
背景情况:
- 质子抑制剂 (PPI) 经常用于治疗诸如GERD和胃潰瘍等疾病.
- 增加的PPI使用引发了对不适当的处方的担忧,导致潜在的副作用和经济负担.
研究的目的:
- 审查与质子抑制剂 (PPI) 使用相关的潜在不良影响.
- 强调在临床实践中评估PPI持续需求的重要性.
主要方法:
- 对研究PPI及其相关不良事件的文献综述.
- 分析证据质量,将PPI与各种副作用联系起来.
主要成果:
- PPI与脆弱性骨折,维生素B12和缺乏以及肠道感染 (例如,Clostridioides difficile) 的风险增加有关.
- 肝硬化患者的并发症和药物相互作用也被认为是不良影响.
- 一些关联得到了强有力的证据的支持,而另一些则需要谨慎解释,因为证据质量较差.
结论:
- 医疗保健提供者应定期评估个人防护剂的适用性,并在适当时考虑停止治疗.
- 对于 PPI 的潜在不良影响和适应症的认识对于安全有效的患者管理至关重要.
相关概念视频
Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors
471
Peptic ulcers, often induced by H. pylori infections or NSAID usage, arise from disruptions in the delicate balance of gastric acid production. Peptic ulcers stem from heightened gastric acid levels due to H. pylori infections or NSAID use. The protective mucus layer diminishes in the presence of these factors, allowing gastric acid to erode the stomach lining and form ulcers.
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
471
Peptic Ulcer Disease IV: Management
110
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
110
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
500
The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
500
Acid Suppressive Drugs for Peptic Ulcer Disease: Antacids
401
In the complex environment of the gastric lumen, excessive acid secretion can lead to the formation or worsening of ulcers within the delicate mucosal layer. Antacids, such as sodium bicarbonate and calcium carbonate, provide relief by neutralizing this acid, transforming it into harmless salt and water. This neutralization process raises the gastric pH from a highly acidic level of 1 to a more basic 3-4, reducing the acidity within the stomach.
However, this neutralization reaction between...
However, this neutralization reaction between...
401
Acid Suppressive Drugs for Peptic Ulcer Disease: Histamine H2-Receptor Antagonists
517
Histamine H2 receptors, which are intricately located on the basolateral membrane of parietal cells, play a crucial role in modulating gastric acid secretion. When released from enterochromaffin-like cells, histamine engages H2 receptors, initiating the cyclic AMP (cAMP) pathway. In this pathway, adenylyl cyclase converts ATP into cAMP, elevating intracellular cAMP levels. The activation of protein kinase A follows, stimulating the proton pump. This stimulation prompts the secretion of hydrogen...
517
Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors
465
Peptic ulcer disease, commonly called PUD, represents a multifaceted condition characterized by disruptions in the lining of the gastrointestinal (GI) tract. Central to the protection of the gastrointestinal lining is the mucosal-bicarbonate barrier. This physiological defense mechanism is a formidable shield against the corrosive effects of gastric acid and pepsin secretion in the stomach. Its role is pivotal in maintaining the structural integrity of the stomach's inner lining.
465


